DCVax®-L is a vaccine, developed by Northwest Biotherapeutics, that is made from each patient’s own dendritic cells. Dendritic cells are a type of immune cell that function to help the body’s immune system recognise and attack tumour cells.
Is DCVax FDA approved?
DCVax-Brain is currently undergoing phase II clinical trials, and DCVax-Lung recently received approval from the US FDA for phase I clinical trials.
What is the survival rate for Glioblastoma?
Glioblastoma survival The average survival time is 12-18 months – only 25% of glioblastoma patients survive more than one year, and only 5% of patients survive more than five years.
Is DCVax available in the UK?
Right now, DCVax®-L can only be made available to patients on a very limited basis through the UK Specials programme, as there is currently no regulatory approval.
How much does DCVax cost?
NWBT’s DCVax® will be priced in the range of $37,000 per year for up to 3 years of treatments. In NWBT’s Phase I/II multi-center clinical trial in late stage, metastatic prostate cancer, DCVax® added 18 months of patient survival (to reach overall survival of 38.7 months).
Can you live a long life with glioblastoma?
Only 10% of people with glioblastoma survive five years. However, here I am, 10 years after being diagnosed with the most aggressive form of brain cancer, and I’m not only surviving – I’m thriving.
Is Keytruda a good drug?
Keytruda’s effectiveness for NSCLC In clinical studies, Keytruda has been found to be effective in treating different forms of NSCLC. In a clinical study, Keytruda (used with certain chemotherapy drugs) was effective as first-line treatment for metastatic, non-squamous NSCLC that had not been treated in the past.
